@article { author = {Faghihloo*, Ebrahim and Mirzaei, Habibollah and Akbari, Abolfazl and Goudarzi, Hossein}, title = {Silibinin upregulates E-cadherin expression in MKN-45 human gastric cancer cells}, journal = {Research Journal of Pharmacognosy}, volume = {5}, number = {3}, pages = {41-46}, year = {2018}, publisher = {- The Iranian Society of Pharmacognosy - Shahid Beheshti University of Medical Sciences}, issn = {2345-4458}, eissn = {2345-5977}, doi = {10.22127/rjp.2018.64874}, abstract = {Background and objectives:  Gastric cancer is currently known as one of the most important causes of cancer-driven death all over the world. In patients with gastric cancer, a significant proportion of death occurs due to metastasis. On the other hand, down modulated E-cadherin level has been reported as an important contributor to tumor cell invasion and metastasis. In this regard, the present work was aimed to evaluate the impact of silibinin, a flavonolignan with established anti-tumor efficacy, on cell viability and E-cadherin expression in the gastric cancer cell line MKN-45. Methods: To determine cell viability, MTT assay was performed 48 h after silibinin treatment (at concentrations of 100, 200 and 400 μM). In addition, quantitative real-time PCR was done following total RNA extraction and cDNA synthesis, to assess E-cadherin level in cells treated with silibinin. Results: The MTT results showed concentration-dependent reducing effect of silibinin on viability of MKN-45 cells. The findings of quantitative real-time PCR analysis demonstrated upregulated E-cadherin expression in cells treated with silibinin (significantly (p≤ 0.05) at concentration of 200 μM) compared to the control cells. Conclusions: The current study suggested that silibinin may exert anti-migratory/invasive effects on gastric cancer cells by enhancing E-cadherin expression, which needs to be further investigated.  }, keywords = {E-cadherin,Gastric cancer,MKN-45,silibinin}, url = {https://www.rjpharmacognosy.ir/article_64874.html}, eprint = {https://www.rjpharmacognosy.ir/article_64874_255a41e4dff91aae430ce6eeff01b12a.pdf} }